Chemo plus immunotherapy for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that has grown into the muscle layer (stage T2 or T3) but hasn't spread to lymph nodes or other organs.
- You are 18 years or older and in generally good health (able to do daily activities without much help).
- You are able to receive cisplatin chemotherapy (your doctor will check this).
- You haven't had chemotherapy or immunotherapy before for this type of bladder cancer.
- You haven't had radiation therapy to the bladder or a transplant of any kind.
- You don't have an active autoimmune disease or serious infection, and you're not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests a combination of two drugs, sacituzumab govitecan and zimberelimab, to treat muscle-invasive bladder cancer without removing the bladder. It's for patients who cannot or choose not to have bladder removal surgery or standard chemotherapy.
This trial tests a combination of two drugs for people with muscle-invasive bladder cancer who cannot receive cisplatin chemotherapy. The drugs target cancer cells and may help the body's immune system fight the tumor.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.